Publication | Closed Access

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Advanced Breast CancerBreast OncologyOncologyMedicinePhase Iii TrialClinical TrialsBreast CancerPharmacotherapyFirst-line TreatmentCancer TreatmentPharmacology